Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
4.883
+0.133 (2.80%)
Nov 5, 2024, 1:16 PM EST - Market open

Elicio Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Selling, General & Admin
12.1711.95.637.5432.8
Research & Development
29.1623.8518.117.9312.729.54
Operating Expenses
41.3335.7523.7325.4715.7212.34
Operating Income
-41.33-35.75-23.73-25.47-15.72-12.34
Interest Expense
-0.09-1.06-3.6-0.88--
Interest & Investment Income
0.610.370.0700.010.08
Currency Exchange Gain (Loss)
0.360.2----
Other Non Operating Income (Expenses)
1.780.43-0.95-0.05--
EBT Excluding Unusual Items
-38.67-35.8-28.21-26.4-15.71-12.26
Other Unusual Items
00.610---
Pretax Income
-38.67-35.2-28.21-26.4-15.71-12.26
Net Income
-38.67-35.2-28.21-26.4-15.71-12.26
Net Income to Common
-38.67-35.2-28.21-26.4-15.71-12.26
Shares Outstanding (Basic)
105015114
Shares Outstanding (Diluted)
105015114
Shares Change (YoY)
896.37%1500.08%-97.93%42.39%172.21%-
EPS (Basic)
-4.01-6.96-89.27-1.73-1.46-3.11
EPS (Diluted)
-4.01-6.96-89.27-1.73-1.46-3.11
Free Cash Flow
-36.22-32.76-22.83-24.46-16.9-9.78
Free Cash Flow Per Share
-3.76-6.48-72.26-1.60-1.58-2.48
EBITDA
-41-35.36-23.34-25.22-15.53-12.23
D&A For EBITDA
0.330.380.390.250.190.11
EBIT
-41.33-35.75-23.73-25.47-15.72-12.34
Source: S&P Capital IQ. Standard template. Financial Sources.